Baumrin Emily, Loren Alison W, Falk Sandy J, Mays Jacqueline W, Cowen Edward W
Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
Blood and Marrow Transplant, Cell Therapy and Transplant Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23.
Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation and a leading cause of long-term morbidity, nonrelapse mortality, and impaired health-related quality of life. The skin is commonly affected and presents heterogeneously, making the role of dermatologists critical in both diagnosis and treatment. In addition, new clinical classification and grading schemes inform treatment algorithms, which now include 3 Federal Drug Administration-approved therapies, and evolving transplant techniques are changing disease epidemiology. Part I reviews the epidemiology, pathogenesis, clinical manifestations, and diagnosis of cGVHD. Part II discusses disease grading and therapeutic management.
慢性移植物抗宿主病(cGVHD)是异基因造血细胞移植的主要并发症,也是导致长期发病、非复发死亡率及健康相关生活质量受损的主要原因。皮肤是常见的受累部位,表现多样,这使得皮肤科医生在诊断和治疗中发挥着关键作用。此外,新的临床分类和分级方案为治疗算法提供了依据,目前治疗算法包括3种美国食品药品监督管理局批准的疗法,并且不断发展的移植技术正在改变疾病的流行病学。第一部分回顾了cGVHD的流行病学、发病机制、临床表现及诊断。第二部分讨论疾病分级及治疗管理。